PTPRC and neoplasm: We observed, that P2Et-treated mice had higher numbers of spleen conventional DCs (CD45+, CD220−, CD11c+) with increased surface expression of co-stimulatory molecules such as CD86, CD40, MHCII and CD70, suggesting that in vivo P2Et treatment actually enhances the immunogenicity of tumor cells (Figures 7a and b).